Sign inJoin waitlistJoin the waitlist

Thor Halfdanarson

Program Director · Mayo Clinic College of Medicine and Science

Credentials: · · · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2006–2009
Reykjavik Hospital
2003–2006
Reykjavik Hospital
1999–2003
Internal Medicine
Reykjavik Hospital
1996–1999
Psychiatry and Emergency Medicine) Reykjavik Hospital
1995–1996
Faculty of Medicine, University of Iceland
1991–1995

Research

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2019 · 739 citations
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
Annals of Oncology · 2008 · First of 4 authors · Corresponding · 675 citations

Mohamad Sonbol
49 papers · 1 as a fellow
Mark Truty
36 papers
Rory Smoot
29 papers
Hallbera Gudmundsdottir
27 papers · 27 as a fellow
Robert McWilliams
27 papers
Michael Kendrick
25 papers
SC
Sean Cleary
25 papers
DN
David Nagorney
24 papers
Cornelius Thiels
22 papers
Patrick Starlinger
22 papers · 22 as a resident
Susanne Warner
22 papers
Tanios Bekaii-Saab
22 papers

Clinical trials

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Site PI · Recruiting · Phase 1, Phase 2
Perspective Therapeutics
2023–2029
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2027